Is Egrifta (Tesamorelin) Legal in Ohio?

What Is Tesamorelin and Why Does Legal Status Matter?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). The brand Egrifta (tesamorelin 2 mg for injection, Theratechnologies) received FDA approval in November 2010 specifically to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. A reformulated 1 mg strength, Egrifta SV, was approved in 2019.

Legal status matters for two reasons. First, the peptide market is saturated with non-pharmaceutical-grade vials sold for "research use only," a category that exists in a federal gray area and does not protect a patient or clinician under Ohio law. Second, insurance coverage, liability, and compounding pharmacy access all hinge on whether a prescriber and dispensing pharmacy are operating within the federal and state legal framework.

The Federal Baseline

The federal framework governs tesamorelin before Ohio state law even enters the picture.

Tesamorelin is an FDA-approved drug. It is not listed as a scheduled substance under the Controlled Substances Act (CSA). The FDA drug database confirms the NDA approval under NDA 022505. Because it is approved, federal law (21 U.S.C. §353) requires it to be dispensed only on a licensed prescriber's valid prescription. Selling tesamorelin without a prescription or outside a licensed pharmacy violates the Federal Food, Drug, and Cosmetic Act (FD&C Act), regardless of which state you are in.

Ohio State Law Layer

Ohio does not add a separate schedule for tesamorelin beyond the federal baseline.

The Ohio Revised Code (ORC) Chapter 3719 governs controlled substances, and tesamorelin does not appear on any Ohio schedule. The Ohio State Medical Board regulates physician prescribing under ORC Chapter 4731. Ohio pharmacy practice falls under ORC Chapter 4729 and Ohio Administrative Code (OAC) 4729. A prescriber writing tesamorelin in Ohio must hold an active Ohio medical license, write the prescription for a legitimate medical purpose, and maintain a valid patient-prescriber relationship. These are standard requirements that apply to any prescription drug.

FDA-Approved Egrifta: The Clearest Legal Path in Ohio

Approved Indication and Evidence

The FDA approved Egrifta solely for the reduction of excess abdominal fat in HIV-1-infected patients with lipodystrophy. The key Phase 3 trials (LIPO-010 and LIPO-011, combined N=816) demonstrated a mean visceral adipose tissue (VAT) reduction of approximately 15% at 26 weeks compared with placebo, measured by CT scan. Both trials are summarized in the FDA prescribing information.

If you have HIV-associated lipodystrophy and an Ohio-licensed prescriber writes a prescription for Egrifta, you are on the most legally straightforward path available.

Off-Label Prescribing in Ohio

Off-label prescribing is legal. The FDA does not regulate the practice of medicine, and Ohio's medical practice act does not prohibit physicians from prescribing approved drugs for unapproved uses. The American Academy of Family Physicians notes that off-label prescribing is an accepted, lawful component of clinical practice in the United States. The FDA's own guidance confirms that off-label use is legal for licensed practitioners.

Off-label uses of tesamorelin studied in clinical research include growth-hormone deficiency and cognitive function in older adults. A 2012 paper in JAMA (Clemmons et al.) and later work published in the Journal of Clinical Endocrinology and Metabolism have examined tesamorelin's GH-stimulating effects in non-HIV populations. These uses are investigational; a prescriber writing tesamorelin off-label in Ohio should document medical necessity thoroughly.

Cost and Insurance in Ohio

Egrifta and Egrifta SV are expensive brand drugs. Without assistance, monthly costs can reach $4,000 to $6,000. Ohio Medicaid covers Egrifta for the approved HIV-lipodystrophy indication with prior authorization. Private insurers in Ohio generally require the same. Off-label prescriptions are typically not covered, making compounded tesamorelin a cost driver for patients seeking it for non-approved indications.

Compounded Tesamorelin in Ohio: What Is and Is Not Legal

503A Compounding Pharmacies (Patient-Specific)

Section 503A of the FD&C Act allows state-licensed compounding pharmacies to prepare drug preparations for individual patients when a licensed prescriber issues a patient-specific prescription. The pharmacy must use a bulk drug substance that appears on the FDA's 503A "Category 1" list (substances that have been evaluated and are permissible for compounding) or that meets the criteria under the statute.

Tesamorelin is not currently on the FDA's 503A Category 1 approved bulk substances list, nor has the FDA placed it on the "Category 2" negative list. This means tesamorelin occupies an interim status for 503A compounding. The FDA has not issued a final rule either permitting or prohibiting it as a bulk substance for 503A pharmacies. Ohio-based 503A pharmacies should not be compounding tesamorelin using bulk raw material until FDA finalizes its status. Patients who receive compounded tesamorelin from a 503A pharmacy using bulk substance are receiving a preparation whose legal footing at the federal level is unsettled.

The Ohio State Board of Pharmacy follows federal USP and FDA compounding standards. State Board guidance is available at the Ohio Board of Pharmacy website and references FDA's compounding rules directly.

503B Outsourcing Facilities

Section 503B outsourcing facilities operate under FDA oversight, produce drugs without individual patient prescriptions (in bulk for office use), and must meet current Good Manufacturing Practice (cGMP) standards. A 503B facility may compound a drug that is not on the FDA-approved drugs list if it is not a copy of a commercially available drug and meets other statutory criteria.

Here lies a practical complexity. Because Egrifta is an FDA-approved, commercially available drug, a 503B facility compounding tesamorelin as a direct copy of Egrifta would likely violate the prohibition on copying commercially available drugs under FD&C Act §503B(a)(1). A 503B facility could potentially compound a different formulation (for example, a different concentration or a combination preparation) if clinical differentiation is documented, but this requires individualized FDA and legal analysis.

"Research Chemical" Tesamorelin: Not a Legal Path for Patient Use

Tesamorelin vials labeled "not for human use" or "for research purposes only" are sold online and are not legal for patient administration. Under the FD&C Act, a drug intended for human use that lacks FDA approval or compounding-law compliance is adulterated or misbranded, regardless of labeling. An Ohio prescriber who directs a patient to purchase such vials faces Ohio Medical Board disciplinary exposure under ORC §4731.22 for unprofessional conduct. Patients themselves are generally not prosecuted for personal possession of a non-scheduled drug, but the supply chain violates federal law.

The framework below summarizes the four access paths for Ohio patients, rated by legal clarity:

| Access Path | Legal Clarity | Notes | |---|---|---| | Brand Egrifta via licensed Ohio pharmacy | High | Requires valid Rx; covered for approved indication with PA | | Off-label Rx for brand Egrifta | Moderate-High | Legal; insurance coverage unlikely off-label | | 503A compounded tesamorelin | Uncertain (federal) | Bulk-substance status not finalized by FDA | | 503B outsourced compounded tesamorelin | Conditional | Cannot be direct copy of commercially available Egrifta | | "Research use only" vials | Not legal for patient use | Violates FD&C Act regardless of state |

How to Get a Tesamorelin Prescription in Ohio

Step 1: Establish Care with a Licensed Ohio Prescriber

You need a physician (MD or DO), nurse practitioner, or physician assistant holding an active Ohio license. Endocrinologists, HIV medicine specialists, and hormone-therapy clinics are the most common prescribers. The prescriber must conduct a clinical evaluation, document medical necessity, and create a record supporting the prescription. Telemedicine is legal in Ohio for prescription of non-controlled drugs; the prescriber must be licensed in Ohio and must comply with the Ohio Telehealth Act (ORC §4743.09).

Step 2: Confirm the Indication or Document Off-Label Rationale

For HIV-associated lipodystrophy, the prescriber orders standard brand Egrifta and works with the insurer for prior authorization. For off-label use (for example, growth-hormone deficiency evaluation or other investigational indication), the prescriber should document:

• Baseline IGF-1 level and growth hormone stimulation test results
• Documented medical necessity with references to published literature
• Discussion of the off-label status with the patient and signed informed consent
• The specific preparation to be dispensed and from which licensed pharmacy

Step 3: Choose a Dispensing Pharmacy Carefully

For brand Egrifta, any Ohio-licensed or out-of-state pharmacy licensed to ship to Ohio may dispense the prescription. For compounded tesamorelin, you and your prescriber should verify that the pharmacy holds either an Ohio 503A license or an FDA-registered 503B status, and should request documentation of the pharmacy's position on the FDA bulk-substance status question before dispensing.

Step 4: Telehealth Platforms as an Access Route

Several telehealth platforms operate legally in Ohio and employ or contract with Ohio-licensed prescribers who are familiar with peptide therapy and hormone optimization. These platforms can conduct initial evaluation, order labs, and write prescriptions that are sent to licensed compounding or retail pharmacies. The Federation of State Medical Boards' telemedicine policy provides the national standard that Ohio has largely adopted.

Clinical Pharmacology Relevant to Ohio Prescribers

Mechanism and Dosing

Tesamorelin binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile growth hormone release. The FDA-approved dose is 2 mg subcutaneously once daily (Egrifta) or 2 mg once daily (Egrifta SV, 1 mg/mL concentration). The full prescribing information is on FDA's label database.

Peak GH concentrations occur approximately 30 minutes post-injection. Half-life is roughly 26 minutes, necessitating daily administration.

Efficacy Data Ohio Prescribers Should Know

The LIPO-010 trial (N=412, 26 weeks) showed a mean reduction of 17.8 cm² in VAT area by CT scan in the tesamorelin group versus 1.5 cm² in placebo (P<0.001). These data appear in the published trial record at NEJM. Triglycerides also fell by approximately 50 mg/dL compared with placebo in the tesamorelin arm of pooled analyses.

For the off-label cognitive application, a randomized controlled trial published in JAMA (Baker et al., 2012, N=152) showed that 20 weeks of tesamorelin 1 mg/day improved executive function scores compared with placebo in older adults without HIV. The study is indexed on PubMed.

Safety and Contraindications

The main adverse effects are injection-site reactions (up to 25% of patients in trials), fluid retention, arthralgia, and peripheral edema. Tesamorelin is contraindicated in patients with active malignancy, disruption of the hypothalamic-pituitary axis (for example, from pituitary surgery or radiation), and pregnancy. The FDA label details the full contraindication list.

Because tesamorelin raises IGF-1, baseline and periodic IGF-1 monitoring is standard practice. The Endocrine Society's clinical practice guidelines on GH deficiency in adults recommend IGF-1 monitoring for GH-axis therapies. The 2019 Endocrine Society guideline is available at endocrine.org.

Ohio-Specific Regulatory Contacts and Resources

Ohio prescribers or patients with questions about tesamorelin access can contact the following bodies directly:

• Ohio State Medical Board: 614-466-3934 or med.ohio.gov
• Ohio State Board of Pharmacy: 614-466-4143 or pharmacy.ohio.gov
• FDA MedWatch and Drug Information: fda.gov/drugs

The Ohio Board of Pharmacy publishes updated compounding guidance and references FDA's human drug compounding page for 503A and 503B compliance questions. If a pharmacy cannot produce a 503A or 503B registration certificate, patients and prescribers should treat that as a red flag.

What Ohio Patients Are Asking Their Prescribers

The most common clinical question from Ohio patients considering tesamorelin is whether they can access it for body-composition improvement or metabolic health in the absence of an HIV diagnosis. The honest clinical and legal answer has two parts.

First, off-label prescribing is legally permissible in Ohio. A prescriber who believes tesamorelin is medically appropriate for a specific patient, documents that reasoning, obtains informed consent, and writes a prescription is acting within Ohio law.

Second, the compounding pharmacy supplying the prescription must be operating on firm legal footing. Given that tesamorelin's 503A bulk-substance status is not finalized, the most defensible supply path for non-HIV patients is either brand Egrifta (expensive but unambiguous) or a 503B-registered outsourcing facility that can document why its formulation is clinically distinct from commercially available Egrifta.

The Endocrine Society's 2023 scientific statement on GH and related secretagogues states: "GHRH analogues including tesamorelin have demonstrated consistent GH-stimulating and metabolic effects in controlled trials, but use outside FDA-approved indications should be accompanied by rigorous informed consent and monitoring protocols." The statement is available through academic.oup.com.